Article

Pharmacological CDK4/6 inhibition promotes vulnerability to lysosomotropic agents in breast cancer

2024-08-23

Abstract excerpt

Breast cancer is a leading cause of mortality worldwide. Pharmacological inhibitors of Cyclin- Dependent Kinases (CDK) 4 and 6 (CDK4/6i) inhibit breast cancer growth by inducing a senescent-like state. However, the long-term treatment efficacy remains hindered by the development of drug resistance. Clearance of senescent-like cancer cells may extend the durability of treatment. In this study, we showed that CDK4/6...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b4cf0c7b-98c4-5e15-915a-7d7e08487a4f
DOI: 10.1101/2024.08.22.609150

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Pharmacological CDK4/6 inhibition promotes vulnerability to lysosomotropic agents in breast cancerDOI 10.1101/2024.08.22.609150Read

Pharmacological CDK4/6 inhibition promotes vulnerability to lysosomotropic agents in breast cancerSemantic proximity Read

Lysosomal trapping of palbociclib and its functional implicationsSemantic proximity Read

Non-Canonical Senescence Phenotype in Resistance to CDK4/6 Inhibitors in ER-Positive Breast CancerSemantic proximity Read

Pharmacological CDK4/6 inhibition reveals a p53‐dependent senescent state with restricted toxicitySemantic proximity Read

Targeting the LIPH-CD36 axis potentiates CDK4/6 inhibition in ER+ breast cancerSemantic proximity Read

Applications and mechanisms of the cyclin-dependent kinase 4/6 inhibitor, PD-0332991, in solid tumorsSemantic proximity Read

Exploiting targeted degradation of cyclins and cyclin-dependent kinases for cancer therapeutics: a reviewSemantic proximity Read

Resistance to abemaciclib is associated with increased metastatic potential and lysosomal protein deregulation in breast cancer cellsSemantic proximity Read

Broad-spectrum kinome profiling identifies CDK6 upregulation as a driver of lenvatinib resistance in hepatocellular carcinomaSemantic proximity Read

The spindle assembly checkpoint is a therapeutic vulnerability of CDK4/6 inhibitor–resistant ER + breast cancer with mitotic aberrationsSemantic proximity Read

Thermal proteome profiling of breast cancer cells reveals proteasomal activation by CDK4/6 inhibitor palbociclib.Semantic proximity Read

Single-cell morphological and transcriptome analysis unveil inhibitors of polyploid giant breast cancer cells in vitroSemantic proximity Read